Skip to main content
Defining and Treating High Risk HR-positive/HER2-Negative Early Breast Cancer
Read More
Online First
Original Research, Adverse Events, Infections, Transplant
Posttransplant Cyclophosphamide and Letermovir Influence on Breakthrough CMV Reactivation for Allogeneic Hematopoietic Stem Cell Transplant Patients
Gionna Knauss, PharmD; Rachael Lauren Straining, PharmD, BCOP; Gwen Hua, PharmD, BCOP
Read More
Online First
Original Research, Adverse Events, Transplant, Drug Resistance, Oncology Pharmacy Programs/Protocols
A Standardized Pharmacist-Guided Emesis Workflow: Implementation of Clinical Practice Guideline–Consistent Antiemetic Therapy in Children Undergoing Hematopoietic Stem Cell Transplantation
Anny Chan, PharmD; Evan Abrass, PharmD; Dwight Barry, PhD; Inara Sipols, PharmD; Paul Carpenter, MBBS; Joseph Niedner, PharmD, et al.
Read More
Online First
Original Research
Impact of a Home Hydration Program on Patients Receiving Chemotherapy at a Pediatric Tertiary Ambulatory Cancer Center
Patrick J McBride
Patrick J. McBride, PharmD, BCOP
Read More
Online First
Original Research, Adverse Events, Disparities in Oncology Care, Dose Escalation/Reduction, Immunotherapy, Multiple Myeloma
Characterizing Lenalidomide Dose Modifications Among Black and Non-Black Patients Receiving Induction Therapy for Newly Diagnosed Multiple Myeloma
Laura Fan Sun, PharmD, BCOP; Natalie Brumwell, PharmD; Kevin Hall, PharmD; Kristina Murphy, PharmD; Jeffrey Switchenko, PhD; Yichun Cao, MPH, et al.
Read More
Online First
Original Research, Lymphoma, Methotrexate, Chemotherapy
CNS Prophylaxis in Patients With Diffuse Large B-Cell Lymphoma
Hannah Bunn, PharmD; Sheniece Carpenter, PharmD, MSCR, BCPS; Zachary Kritzer, PharmD; Scott Christofferson, PharmD, BCPS; Sara Wiser, PharmD; Walter Russell Laundon, PharmD, MS, BCPS
Read More
HOPA Corner
Executive Summary—2026 HOPA Scope of the Oncology Pharmacist Provider
Kelly M. Brunk, PharmD, MBA, BCOP; Jill Bates, PharmD, MS, BCOP, DipACLM, FASHP; Eve M. Segal, PharmD, BCOP; Sara L. Fleszar, PharmD, BCOP; Julie Kennerly-Shah, PharmD, MS, MHA, BCPS; and Lisa M. Holle, PharmD, BCOP, FHOPA, FISOPP, FCPA, FCCP
Read More
Online First
Original Research, Case Reports, Breast Cancer, Chemotherapy, Immunotherapy
Outcomes in Early-Stage Triple-Negative Breast Cancer With Dose-Dense Doxorubicin and Cyclophosphamide as Part of Pembrolizumab-Based Regimens
Mikaila Eross, PharmD; Mitchell Mirabile, PharmD, BCOP; Danielle Roman, PharmD, BCOP; Rachelle Nadour, PharmD, BCOP; Christie Hilton, DO
Read More
FDA Updates, Pancreatic Cancer
FDA Approval of Daraxonrasib: A New Era for Pancreatic Cancer Treatment
Read More
CDK4/6 Inhibitors in Early Breast Cancer
Case-Based Exchanges
High-Risk, Node-Positive, HR-Positive/HER2-Negative Early Breast Cancer
Neil M. Iyengar, MD, Annalise Labatut, PharmD, BCOP
Read More
Page 1 of 200
Results 1 - 10 of 1993